



## Press Release

### **Blue Sail Medical and Biosensors International achieve a milestone towards entering the Structural Heart business, as they finalize the acquisition of Switzerland based NVT AG.**

Singapore, 09 June 2020 – Blue Sail Medical announced today the completion of its acquisition of NVT AG, Muri (Argau, Switzerland), which was previously communicated on September 20, 2019.

The deal closure was publicly announced on the Shenzhen Stock Exchange on the 09 June 2020 and will leverage the capabilities and experience in interventional cardiology of its subsidiary, Biosensors International Group.

The finalization of this deal brings together NVT's expertise in innovative Transcatheter Aortic Valve Implantation technology, and Biosensors' solid track record in Interventional Cardiology.

*"The closing of this transaction represents a new and exciting era for the company, and specifically the new Structural Heart business unit, as we seek to continue improve patients' lives through pioneering medical technology. It broadens the company's assets and will provide strategic growth opportunities, particularly in the transcatheter aortic valve replacement market. Together, we look forward to leveraging and further accelerating Biosensor's drive to deliver the greatest possible patient outcomes."* commented Mr Brian Fan Yang, Blue Sail Executive Committee Member & CEO Biosensors International Group.

#### **About ALLEGRA™ TAVI system**

The ALLEGRA transcatheter aortic valve implantation system stemmed from NVT strong R&D pipeline and manufacturing capabilities based in Germany. The company, dedicated to Transcatheter Aortic Valve Implantation (TAVI) has developed and launched the ALLEGRA™ TAVI system, which received CE mark in 2017.

It is a self-expanding supra-annular transcatheter aortic valve, which presents unique design features and similar event rates compared to contemporary devices.

The most recent data, presented during PCR London Valves 2019, shows positive outcomes for the ALLEGRA TAVI system in a Valve-in-Valve setting at 12 months in the VIVALL trial. On 29 April 2020, the device received CE approval for Valve-in-Valve indication.

The TAVI market is growing at about 15% worldwide, Europe and the US being the main markets to date. In EMEA, the market is forecasted to reach nearly 85,000 procedures next year. China is also seen as a very important growth market over the next five years.

For more information about ALLEGRA™, please visit <https://www.nvt-med.com/overview-products-cardiac-valves.html>

### **About Blue Sail Medical (SZ.002382)**

Blue Sail Medical has established a development strategy in cardiovascular and cerebrovascular diseases area. The company focuses on both high value consumables (cardiovascular and interventional cardiac surgery related devices), and low/medium value consumables (medical gloves, health protective gloves, first aid kits, medical dressings). The acquisition of NVT will capture a great M&A opportunity for Blue Sail Medical to obtain quality assets in the TAVI business.

For more information about Blue Sail Medical, please visit <http://www.bluesail.cn/en/index.php>

### **About Biosensors International Group**

Biosensors Intl. is a subsidiary of Blue Sail Medical, with 25 years experience in designing, manufacturing and marketing innovative medical devices that improve patients' lives, including devices for Percutaneous Coronary Intervention. The company has worldwide operations, and with the combination of direct sales teams and a worldwide distribution networks, it serves the needs of the healthcare community.

For more information about Biosensors Intl., please visit <https://www.biosensors.com/intl/>